Pharmaceutical companies and the third world [11]

Lancet

Volumn 361, Issue 9363, 2003, Pages 1136-1137

  Pai, Sanjay A ^a   Lakshmi, P K ^b   Rao, B C ^d   Sahni, Peush ^c  

^a MANIPAL HOSPITAL   (India)

^b Karnataka State Higher Education Council   (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; CISAPRIDE; DIPYRONE; NIMESULIDE; PHENYLBUTAZONE; PHENYLPROPANOLAMINE; TERFENADINE;

DEVELOPING COUNTRY; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HUMAN; INDIA; LETTER; MEDICAL ETHICS; MEDICAL INFORMATION; PRIORITY JOURNAL; SIDE EFFECT; UNITED STATES;

EID: 0037471819     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12881-4     Document Type: Letter

References (5)

1. Newton P.N., White N.J., Rozendaal J.A., Green M.D. Murder by fake drugs. BMJ. 324:2002;800-801.
2. Komesaroff P.A., Kerridge I.H. Ethical issues concerning the relationships between medical practitioners and the pharmaceutical industry. Med J Aust. 176:2002;118-121.
3. Lexchin J. Interactions between physicians and the pharmaceutical industry: what does the literature say? Can Med Assoc J. 149:1993;1401-1407.
4. Rao B.C. Withdrawing drugs: need for global uniformity. Natl Med J India. 13:2000;165.
5. Latham P.M. General remarks on the practice of medicine. Strauss M.B. Familiar medical quotations. 1968;124 Little, Brown and Company, Boston. chapter 4.